Abstracts tagged "Vitamin D and osteoporosis"

Abstract Number: 2328 • 2018 ACR/ARHP Annual Meeting
Current Factors Associated with Insufficient Vitamin D Status in Patients with Osteoporosis
Sandeep Dhillon¹, Arzoo Alam², Matthew Wong-Pack³, Arthur Lau⁴, Karen A. Beattie⁵ and Jonathan D. Adachi^6,7, ¹Department of Medicine, McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴50 Charlton Avenue East, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Medicine, McMaster University, Hamilton, ON, Canada, ⁶Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: In 2010, the Canadian Osteoporosis guidelines recommended that patients with osteoporosis be supplemented with vitamin D and to achieve serum levels ≥75nmol/L. Past studies,…
Abstract Number: 2187 • 2016 ACR/ARHP Annual Meeting
Vitamin D Levels and Fragility Fractures in Postmenopausal Portuguese Women- Results from Epireumapt
Ana M. Rodrigues^1,2,3, Ana Catarina Rodrigues⁴, Monica Eusebio³, Pedro Simões Coelho⁵, Jorge M Mendes⁵, Jaime Cunha Branco^1,3,6 and Helena Canhão^1,3, ¹CEDOC, Nova Medical School, Lisbon, Portugal, ²Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ³Portuguese Society of Rheumatology, Lisbon, Portugal, ⁴Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ⁵NOVA IMS, Universidade Nova de Lisboa, Lisbon, Portugal, ⁶Rheumatology, CHLO, Hospital Egas Moniz, Lisbon, Portugal
Background/Purpose: Vitamin D is implicated in bone homeostasis and its deficiency is associated with a progressive bone loss and fragility fractures. Our aim was to…
Abstract Number: 3174 • 2015 ACR/ARHP Annual Meeting
Vitamin D Binding Protein and Tenofovir-Associated Bone Loss Among Individuals with HIV
Evelyn Hsieh^1,2, Liana Fraenkel¹, Weibo Xia³, Yang Han², Michael Yin⁴, Karl Insogna⁵, Ting Zhu² and Taisheng Li², ¹Section of Rheumatology, Yale School of Medicine, New Haven, CT, ²Department of Infectious Diseases, Peking Union Medical College Hospital, Beijing, China, ³Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China, ⁴Division of Infectious Diseases, Columbia University Medical Center, New York, NY, ⁵Section of Endocrinology, Yale School of Medicine, New Haven, CT
Background/Purpose: Antiretroviral regimens containing tenofovir disoproxil fumarate (TDF) have been associated with decreases in bone mineral density, and elevations in bone turnover markers (BTM) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].